This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Single-cell sequencing | |
|---|---|
| Name | Single-cell sequencing |
| Purpose | High-resolution genomic, transcriptomic, epigenomic profiling |
Single-cell sequencing is a set of laboratory and computational techniques for profiling the genomes, transcriptomes, epigenomes, and other molecular layers of individual cells rather than of bulk tissue samples. Developed through the convergence of innovations from groups associated with Broad Institute, Wellcome Sanger Institute, Harvard University, Stanford University, and Massachusetts Institute of Technology, the field enabled mapping of cellular heterogeneity in contexts ranging from Human Genome Project-era ambitions to modern atlasing efforts such as the Human Cell Atlas and large consortia like the Cancer Genome Atlas. Its rise intersects with advances at institutions including Max Planck Society, European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, and translational programs at hospitals such as Mayo Clinic, Johns Hopkins Hospital, and Memorial Sloan Kettering Cancer Center.
Single-cell sequencing originated from methodological breakthroughs in low-input nucleic acid amplification pioneered by laboratories connected to Cold Spring Harbor Laboratory, Stanford University School of Medicine, Harvard Medical School, and the Whitehead Institute. Early landmark publications from teams led by investigators affiliated with Eric Lander-linked groups at the Broad Institute and studies supported by the National Institutes of Health accelerated adoption in developmental biology, immunology, oncology, and neuroscience at centers like Salk Institute and University of California, San Francisco. The approach resolves cell-to-cell variation invisible to bulk assays used in projects such as the ENCODE Project and complements single-molecule methods developed at facilities like European Molecular Biology Laboratory (EMBL).
Laboratory workflows include single-cell isolation, nucleic acid recovery, amplification, library preparation, and high-throughput sequencing on platforms from vendors historically collaborating with research hubs such as Illumina, Pacific Biosciences, and Oxford Nanopore Technologies. Isolation strategies trace back to microfluidics innovations at groups linked to MIT and devices invented in collaborations involving Stanford University engineers; methods include fluorescence-activated cell sorting (FACS) used at institutions like Fred Hutchinson Cancer Research Center, microdroplet encapsulation commercialized by companies working with Harvard University spinouts, and plate-based approaches refined in laboratories at Cold Spring Harbor Laboratory. Template amplification and conversion chemistries—multiple displacement amplification (MDA), multiple annealing and looping-based amplification cycles (MALBAC), and Smart-seq protocols—were developed across academic laboratories including teams from Peking University and University of Cambridge. Multi-omic extensions combine chromatin accessibility assays such as ATAC-seq adapted at groups associated with Broad Institute and methylation measurements derived from bisulfite chemistry optimized in collaborations with Wellcome Sanger Institute.
Clinical and basic-research applications span oncology programs at MD Anderson Cancer Center and Dana-Farber Cancer Institute, immune profiling in projects partnered with National Institutes of Allergy and Infectious Diseases, neurobiology consortia involving Allen Institute for Brain Science, and developmental atlases coordinated by European Bioinformatics Institute affiliates. In cancer, single-cell profiles resolve intratumoral heterogeneity characterized in studies from Memorial Sloan Kettering Cancer Center and inform precision oncology initiatives tied to NCI networks. Immunology uses include single-cell characterization of T cell repertoires in trials at Stanford Medicine and vaccine-response studies linked to Centers for Disease Control and Prevention collaborations. In neuroscience, contributions from researchers at Columbia University, University of Oxford, and Yale University have revealed cellular subtypes implicated in disorders studied at National Institute of Mental Health.
Computational pipelines developed by groups at Broad Institute, European Bioinformatics Institute, Wellcome Sanger Institute, and university groups such as University of California, Berkeley and ETH Zurich address normalization, dimensionality reduction, clustering, and trajectory inference. Popular toolkits and methods originating in labs associated with New York University, University of Toronto, and University of Washington implement algorithms for batch correction, imputation, and integration across modalities; challenges include sparse count matrices, high technical noise, and scalability for consortia-scale datasets produced in projects like the Human Cell Atlas. Databases and visualization portals hosted by entities such as Gene Expression Omnibus-linked resources and repositories curated at European Nucleotide Archive require standardized metadata governed by initiatives involving International Cancer Genome Consortium-style coordination.
Technical artifacts arise from dissociation protocols standardized in clinical centers like Mayo Clinic and enzymatic treatments used in protocols developed at EMBL and Sanger Institute, causing stress-response signatures and loss of spatial context documented in studies from Harvard Medical School and University College London. Dropout events, amplification bias, allelic dropout, and doublet formation remain issues reported across datasets generated at institutions including Broad Institute and Fred Hutchinson Cancer Research Center. Spatial transcriptomics methods that preserve tissue architecture were advanced in collaborations featuring 10x Genomics and academic groups at Karolinska Institute to mitigate loss of locality; nonetheless, trade-offs between throughput and resolution constrain experimental design in translational programs at hospitals such as Cleveland Clinic.
Clinical deployment raises consent, privacy, and data-sharing concerns interfacing with regulations and frameworks developed by World Health Organization, European Commission, U.S. Food and Drug Administration, and national agencies like Health Canada. Large-scale data aggregation across consortia such as the Human Cell Atlas and cancer consortia requires governance aligned with policies from National Institutes of Health and ethical guidance from bioethics centers at Oxford University and Harvard University. Equity issues, intellectual property disputes involving companies spun out of MIT and Stanford University, and implications for indigenous data sovereignty emphasized by organizations like United Nations bodies and national research councils must inform study design and data stewardship.
Near-term advances will be driven by integration of long-read sequencing technologies commercialized by Pacific Biosciences and Oxford Nanopore Technologies, higher-throughput microfluidic devices from industry partners collaborating with MIT and Stanford University, and spatially resolved multi-omics scaled by efforts at Broad Institute and Wellcome Sanger Institute. Cross-disciplinary coordination with neuroscience initiatives at Allen Institute for Brain Science, cancer consortia at NCI, and public–private partnerships involving Chan Zuckerberg Initiative will shape standardized atlases and clinical translation pathways. Ethical frameworks and data infrastructure developed by groups at European Bioinformatics Institute, National Institutes of Health, and World Health Organization will be critical to equitable global deployment.